Abstract
Studies have increasingly shown that carbamoyl phosphate synthetase 1 (
) plays a vital role in the occurrence and development of human malignant disease. Unfortunately, the detailed function of
in the development and prognosis of lung cancer, especially lung adenocarcinoma (LADC), is still not fully understood. In this research, we performed a comprehensive bioinformatics analysis with respect to the function of
in human LADC.
Several biological databases including UALCAN, GEPIA and Oncomine were used to analyze the expression of
in LADC. Meanwhile, TCGA and GEO databases were utilized to analyze relevant clinical data. In addition, databases including Methsurv, etc., were used to analyze
methylation levels in LADC.
The Oncomine platform, UALCAN and gene expression profiling interactive analysis (GEPIA) were used and revealed that the expression levels of
were significantly increased in LADC tissues. Furthermore, we analyzed the methylation level of
in LADC and found that cases with high levels of
showed hypomethylated
. The clinical data from the Wanderer database, which is linked to The Cancer Genome Atlas (TCGA) database, demonstrated that the expression and methylation values of
were both significantly related to the clinical characteristics and prognosis of LADC. Through analysis of the dataset from the Gene Expression Omnibus (GEO) database, we found that the expression level of
was markedly downregulated in human A549 lung cancer cells treated with the chemotherapeutic drug motexafin gadolinium (MGd) in a time-dependent manner.
Our work indicated that
is upregulated in LADC samples and that
might be used as a potential biomarker for the diagnostic and prognostic evaluation of LADC. Determining the detailed biological function of
in LADC tissues will provide promising and insightful information for our further study.
